Molecular mechanisms behind the generation of pro-oncogenic HIV-1 matrix protein p17 variants

J Gen Virol. 2024 Apr;105(4). doi: 10.1099/jgv.0.001982.

Abstract

HIV-1 matrix protein p17 variants (vp17s), characterized by amino acid insertions at the COOH-terminal region of the viral protein, have been recently identified and studied for their biological activity. Different from their wild-type counterpart (refp17), vp17s display a potent B cell growth and clonogenic activity. Recent data have highlighted the higher prevalence of vp17s in people living with HIV-1 (PLWH) with lymphoma compared with those without lymphoma, suggesting that vp17s may play a key role in lymphomagenesis. Molecular mechanisms involved in vp17 development are still unknown. Here we assessed the efficiency of HIV-1 Reverse Transcriptase (RT) in processing this genomic region and highlighted the existence of hot spots of mutation in Gag, at the end of the matrix protein and close to the matrix-capsid junction. This is possibly due to the presence of inverted repeats and palindromic sequences together with a high content of Adenine in the 322-342 nucleotide portion, which constrain HIV-1 RT to pause on the template. To define the recombinogenic properties of hot spots of mutation in the matrix gene, we developed plasmid vectors expressing Gag and a minimally modified Gag variant, and measured homologous recombination following cell co-nucleofection by next-generation sequencing. Data obtained allowed us to show that a wide range of recombination events occur in concomitance with the identified hot spots of mutation and that imperfect events may account for vp17s generation.

Keywords: B cell clonogenic activity; HIV-1 matrix protein p17 variants; evolutionary trajectory; hot spots of mutations; next generation sequencing; recombination events.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • HIV Antigens* / genetics
  • HIV Antigens* / metabolism
  • HIV Infections / genetics
  • HIV Infections / virology
  • HIV Reverse Transcriptase* / genetics
  • HIV Reverse Transcriptase* / metabolism
  • HIV-1* / genetics
  • Humans
  • Mutation
  • gag Gene Products, Human Immunodeficiency Virus* / genetics
  • gag Gene Products, Human Immunodeficiency Virus* / metabolism

Substances

  • p17 protein, Human Immunodeficiency Virus Type 1
  • gag Gene Products, Human Immunodeficiency Virus
  • HIV Antigens
  • HIV Reverse Transcriptase
  • reverse transcriptase, Human immunodeficiency virus 1